bioAffinity Technologies, Inc. BIAF PHARMA
Company Overview
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Why Investors Should Care
Revenue has grown at a 986.6% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.38.
Recent Developments
- Dec 2025 Revenue of $6.16M (-34.2% YoY); net profit $-14.91M.
- Trailing 12 Months Year-on-year growth — revenue +19.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 986.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 986.60% |
| 1 Year: | 19.00% |
Stock Price Performance
| 1 Year: | +6.31% |
| 6 Months: | -43.84% |
| 3 Months: | -62.79% |
| 1 Month: | +16.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)51.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 986.6% over 5 years.
CONS
- Trading 94.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BIAF bioAffinity Technologies, Inc. PHARMA | 8.93 | -6.61 | $5.36M | 0.00% | -131.26% | - | 986.60% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 1.31K | 1.15K | 921 | 19.74K | 298.48K | 2.41M | 2.40M | 2.35M | 1.85M | 1.27M | 1.45M | 1.54M | 1.35M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 1.37M | 1.02M | 942.21K | 900.13K | 928.64K |
| Gross Profit | - | - | 1.16K | 1.00K | 834 | 18.50K | 223.78K | - | - | - | 485.74K | 252.88K | 503.86K | 638.69K | 422.89K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 3.11M | 2.77M | 2.80M | 3.83M | 4.04M |
| Operating Income | -526.29K | -727.04K | -684.12K | -976.16K | -1.56M | -1.78M | -2.29M | -1.95M | -2.09M | -1.97M | -2.63M | -2.52M | -2.29M | -3.19M | -3.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | -2.48M | -3.91M | -4.93M | -3.00M | -3.50M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 15.48K | 10.46K | 5.36K | 13.07K | 14.72K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | -2.65M | -4.03M | -5.05M | -3.13M | -3.63M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 8.70K | 28.98K | 3.18K | 3.18K | 0 |
| Net Income | -1.51M | -1.47M | -88.05K | -4.92M | -1.53M | -1.74M | -2.29M | -1.96M | -2.11M | -2.00M | -2.66M | -4.06M | -5.05M | -3.14M | -3.63M |
| Diluted EPS | - | - | -0.03 | -1.17 | -0.18 | -0.20 | -0.26 | -0.20 | -0.19 | -4.84 | -4.80 | -5.10 | -4.74 | - | -0.81 |
| R&D Expense | 330.77K | 279.85K | 248.42K | 319.74K | 369.62K | 335.12K | 330.38K | 393.64K | 402.43K | 274.50K | 367.39K | 311.37K | 330.59K | - | 349.71K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 4.80K | 2.53M | 9.36M | 6.16M |
| Gross Profit | - | 4.34K | - | - | - |
| Operating Income | -2.21M | -4.01M | -7.97M | -8.95M | -10.57M |
| Net Income | -6.33M | -8.15M | -7.94M | -9.04M | -14.91M |
| Diluted EPS | - | -1.81 | -0.91 | -22.50 | -8.66 |
| R&D Expense | 1.01M | 1.38M | 1.47M | 1.46M | 1.38M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 1.45M | 12.18M | 8.22M | 6.51M | 10.96M |
| Total Equity | -15.07M | -15.79M | 11.04M | 4.86M | 2.60M | 7.28M |
| Cash & Equivalents | - | 1.36M | 11.41M | 2.82M | 1.11M | 6.45M |
| Total Liabilities | - | 13.20M | 1.14M | 3.37M | 3.91M | 3.68M |
| Current Liabilities | - | 13.04M | 1.14M | 2.25M | 3.10M | 2.91M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -2.05M | -4.07M | -6.04M | -7.26M | -9.33M |
| Investing Cash Flow | - | -219.99K | -2.21M | -79.08K | -60.57K |
| Financing Cash Flow | 3.33M | 14.34M | -344.98K | 5.63M | 14.73M |
| Capital Expenditure | - | -219.99K | -22.90K | -79.08K | -60.57K |
| Free Cash Flow | - | -4.29M | -6.06M | -7.34M | -9.39M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 90.3% | - | - | - |
| Operating Margin % | - | -83,511.5% | -314.8% | -95.6% | -171.6% |
| Net Margin % | - | -169,771.2% | -313.4% | -96.6% | -242.0% |
| ROE % | 40.1% | -73.8% | -163.5% | -347.4% | -204.9% |
| ROCE % | 19.0% | -36.3% | -133.5% | -262.7% | -131.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sabby Management, LLC | 4.06% | 24.38K | $229.88K |
| 2 | Blackrock Inc. | 1.10% | 6.58K | $62.10K |
| 3 | Vanguard Capital Management LLC | 0.62% | 3.70K | $34.92K |
| 4 | Geode Capital Management, LLC | 0.57% | 3.40K | $32.04K |
| 5 | J. Safra Sarasin Holding AG | 0.47% | 2.84K | $26.78K |
| 6 | Vanguard Fiduciary Trust Co | 0.34% | 2.07K | $19.53K |
| 7 | Susquehanna International Group, LLP | 0.30% | 1.79K | $16.89K |
| 8 | Jane Street Group, LLC | 0.30% | 1.79K | $16.84K |
| 9 | State Street Corporation | 0.27% | 1.61K | $15.14K |
| 10 | HRT Financial LP | 0.23% | 1.39K | $13.10K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIAF
There are notable gap-ups and gap-downs in today's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxONGpGbmR6bTVqUW8wbTlnZFl2OUJNSU1PbGNSLTVxSW5RVUpKMzZ2M1VOM2JNOTBZTHBjSkMwYU14WVhXakpLVThIWUs1MFNLZlNQUC1TUGhGRXBkZVJVWlNfSl8ybFlfcnRFV2xpUXFLNGhHdFl6QlF2anlwbV9WWTFyZC1MMEF5Yk91ZG…
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxNSWdKRkxLZTItekYtQ0dhbDFGQTBibEZVeEU0Y2ZRNDAwcE5WWGx6TXI0UTN6LWRWWFdFM3ZfNzhGTndVdXp4OUZsTGN0N0FWS3BVTDFnTElwRm1EUjZDazF4dFVfSUtVN3dTelFYek9SeGlmVDBqZ2VKZlROLXk5aXJUV3dIbGhab0pqdg…
bioAffinity will present an update on its lung-cancer test - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOb1UxR2c4U21KYmJjLVM5RDVFS3l3Ui03RUVJbFR1SEJCMjhZTXFIOXFiaFJwbWdQR3VxeXd4eldjc2VvWkVEZXZHYTRYcFdEZ2VjSGwzd1lsbjNLeHBNVE45WnRDa0JvZy1YREpGNEd6YXR2Q0E5SUVGUmpzc3dlWlNYNlFPMUdIbk12bE…
(BIAF) Volatility Zones as Tactical Triggers - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPc0RzdW5jTS1fUEI1NFJKc2FBc1BZZG85Sm9QOTZIZmktWkcwb3ZXN3ZEbFg0Q3BJbUMxbjVxVFNibEtLd0NXbEVEclZaMmtoSUw2RGQ4OWVBVWgydmRabUFEeVJKRE5ZN0psLU1xNjY1YnVJQUw2RE05V1hJMzZoODBScGJmRUhEMktpVl…
BIAF Stock Slides As bioAffinity’s Dilution And Reverse Split Reshape Trading Setup - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMihgFBVV95cUxQZlotWGdvbjUwNnVsZFg1ZlBONkR5WXBXYjB5Y3dEYVZZY2Y5MEVhTjM2cGUwS2hkVjQwREpNRGRJUjVoeV80MTBhQlFqNVJkYU9NNUlfZUwwNENhU2g4UURyMnlNMDVGR2gyRzhDa0VkbWI1N3o1OVlrd0hNZUI0cmx4QllLUQ?oc=5" t…
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - RTTNews
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQYXNrTE5QQmlsZVZJb2NpcVVHdkNHbWRKLUlPZm1rS0hjR0xldWZWOFhSQnpCT2pDTWI3bmdWS2NEY0dXRDlZM1lPa2VQNWJycDdoYXNWY09sUklhaVh5WjhacWVXZXpFSExDN3VFSnZ0YzQtYXA1TzJqRDlqc3NxdjZITFd3bTdQYmNuUG…
BIAF — Frequently Asked Questions
What is the current share price of bioAffinity Technologies, Inc. (BIAF)?
As of 2026-09-19 21:16 PDT, bioAffinity Technologies, Inc. (BIAF) trades at $8.93 on NasdaqCM. Its 52-week range is $4.56 to $157.50.
What is the market capitalisation of BIAF?
bioAffinity Technologies, Inc. (BIAF) has a market capitalisation of $5.36M on NasdaqCM.
What is the P/E ratio of BIAF?
BIAF trades at a trailing price-to-earnings (P/E) ratio of -6.61. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.26.
Is BIAF a good stock to buy?
This page provides a data-driven analysis of bioAffinity Technologies, Inc. (BIAF), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.